Femasys Is Putting Women in Charge of Their Reproductive Health
Femasys's Buy Rating Affirmed by Analyst Jason McCarthy on FemaSeed's Market Success and Robust Clinical Trials
Express News | Femasys Inc : H.c. Wainwright Raises Target Price to $13 From $12
Express News | HC Wainwright & Co. Reiterates Buy on Femasys, Maintains $13 Price Target
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and Femasys (FEMY)
Femasys | 10-Q: Quarterly report
Express News | Femasys Q1 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $271.140K Miss $776.500K Estimate
Express News | Femasys Inc - Believe We Have Sufficient Cash to Fund Operations Into Second Half of 2025
Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140
08:34 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140
Femasys 1Q Sales $271,140 >FEMY
Femasys 1Q Sales $271,140 >FEMY
Express News | Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
Express News | Femasys Inc. Q1 EPS USD -0.17
Femasys Releases Updated Investor Presentation Information
Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential
Femasys Price Target Maintained With a $12.00/Share by Chardan Capital
Femasys Price Target Maintained With a $12.00/Share by Chardan Capital
Femasys Is Maintained at Buy by HC Wainwright & Co.
Femasys Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Femasys, Raises Price Target to $12
HC Wainwright & Co. analyst Emily Bodnar maintains Femasys (NASDAQ:FEMY) with a Buy and raises the price target from $10 to $12.
Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Femasys Q4 EPS $(0.19) Beats $(0.21) Estimate, Sales $213.11K Miss $240.00K Estimate
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 20.83 percent increase over losses of $(0.24) per s
Femasys GAAP EPS of -$0.93, Revenue of $1.07M
No Data